Sickle cell disease is the most frequent haemoglobinopathy in the world. It affects mostly African descent, but is also present in whites in Greece, Turkey, Italy and India. The responsible gene is autosomal co-dominant and only individuals homozygous for the gene are symptomatic. The condition is characterised by haemolytic anaemia crises and cardio-pulmonary, digestive, neurological, ocular and osteo-articular manifestations. Osteo-articular complications are frequent and may compromise harmonious growth. This retrospective study reports the osteo-articular complications associated with sickle-cell disease encountered in our institution from 1975 to 2004. Orthopaedic complications were reported in 79 patients out of 325 who were followed with sickle-cell disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
In this cross-sectional study, we examined the contributions of social support in mitigating the burden that sickle cell disease (SCD) has on the well-being of patients living with the condition. SCD patients ( = 139) in Nigeria completed measures of sickle cell distress, social support, and quality of life. Although we found that SCD distress was strongly associated with poorer quality of life, across domains; social support did not mitigate the impact that SCD distress had on the quality of life of patients.
View Article and Find Full Text PDFPlasma inflammatory and angiogenic protein profiling of patients with sickle cell disease.
Br J Haematol
January 2025
Department of Molecular Hematology, Sanquin Research and Landsteiner Laboratory, Amsterdam, the Netherlands.
In this study, we aimed to explore the inflammatory and angiogenic pathways in sickle cell disease (SCD). We used proximity extension assay technology (Olink) to measure 92 plasma proteins involved in inflammation and angiogenesis. Plasma samples were collected from 57 SCD patients (sickle cell anaemia/HbS-β thalassaemia-thalassaemia) in steady-state and 13 healthy ethnicity-matched healthy controls (HCs).
View Article and Find Full Text PDFWeb-Based Educational Resources for Patients with Sickle Cell Disease: Availability and Reliability.
Int J Gen Med
December 2024
Department of Medicine, College of Medicine, King Faisal University, Alahsa, Saudi Arabia.
Purpose: Arabic is the primary language used in the Middle East, where sickle cell disease (SCD) is prevalent. This study aims to quantify Arabic web educational materials for patients with SCD and provide a descriptive standardized assessment.
Methods And Materials: This retrospective, descriptive study aimed to analyze Arabic websites on SCD through the Discern instrument and JAMA benchmark.
Caregivers' Perceived Threat Of Sickle Cell Disease Complications And Its Association With Hydroxyurea Use Among Children With Sickle Cell Disease In Dar Es Salaam, Tanzania.
Pediatric Health Med Ther
December 2024
Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania.
Purpose: Tanzania is the fifth country with the highest sickle cell disease (SCD) prevalence globally. Although hydroxyurea (HU) is available, only 25% of persons with SCD are reported to use it in Tanzania. Perceived disease threat is associated with medication usage in patients with chronic diseases.
View Article and Find Full Text PDFCurrent and Emerging Approaches Targeting G9a for the Treatment of Various Diseases.
J Med Chem
December 2024
Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Center and Laboratory of Neuro-system and Multimorbidity, Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
G9a, a histone lysine methyltransferase, is instrumental in regulating gene expression through epigenetic modifications. Its overexpression is closely linked to the progression of various human diseases, including cancers. Therefore, targeting G9a enzyme is a promising strategy for treating various diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!